Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022
5.7.2022 12:14:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Center (DERC), will organize the upcoming edition of GLOBALEM, a definitive high power electromagnetic (HPEM) conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005033/en/
Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022 (photo: AETOSWire)
Set to run from November 13 to 17 at St. Regis Abu Dhabi, the conference marks the first high-profile event DERC is hosting after the launch of its prequalification testing facility at Tawazun Industrial Park in Abu Dhabi dedicated to a specific high-energy physics domain.
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center, will offer expertise as General Chair of the organizing committee of GLOBALEM. Other expert members include Dr. Bill Radasky, of Metatech Corporation USA, and Dr. Nicolas Mora from DERC as joint Technical Program Committee co-chairs, as well as Dr. Felix Vega from DERC, Dr. Lars Ole Fichte from the Helmut-Schmidt University in Hamburg, Germany, and Dr. Jane Lehr, from the University of New Mexico, USA, as conference advisors.
Unpacking the challenges and opportunities that currently exist as well as those evolving everyday in the crucial field of electromagnetics, the conference is set to draw the interest of experts from fields as diverse as pulsed power technologies, high voltage generator, microwaveradiation, covering analytical and numerical modeling as well as experimental validation
All eyes will be trained on the Best Student Paper Award (BSPA), with award recipients receiving a certificate and a cash prize of US$500.
Likewise, the Young Scientist Award (YSA) recognizes a young researcher under 35 who has made innovative contributions in fields related to HPEM. Researchers keen to participate in the contest can nominate themselves during the submission process.
For both awards, the last date for the submission of extended abstracts online is July 1, 2022. Acceptance confirmations and nominations will be completed by August 15, and September 15 is the last date for the final review and submission of full papers and award nominations. Early bird registration is open until September 30, 2022.
Highlighting the significance of the conference for the TII ecosystem and for Abu Dhabi as well, Dr. Kasmi said: “The GLOBALEM conference promises to be a game changer for the region. High Power Electromagnetics is one of those hot areas in focus today for us at DERC, given the varied number of applications and sectors it straddles – from your everyday generators, motors, and transformers, to maglev trains, and astronomy to health care and everything in between. We are even focusing on new innovations that can treat certain types of cancer. Being able to convene so many global experts in Abu Dhabi is unprecedented and is a big deal for TII and the region.”
For more information on the GLOBALEM Conference 2022, and to submit scientific papers please visit: https://globalem2022.com/submission.php
About the Technology Innovation Institute (TII)
The Technology Innovation Institute (TII) is the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), and a leading global scientific research center that focuses on shaping breakthrough solutions and new-age technology capabilities. In working with exceptional talent, universities, research institutions and industry partners from around the world, TII connects an intellectual community and contributes to building a thriving R&D ecosystem that elevates the status of Abu Dhabi and the UAE as a global hub for innovation. For more information, please visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005033/en/
Contact information
Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom